Botanix Pharmaceuticals Ltd  

(Public, ASX:BOT)   Watch this stock  
Find more results for bot
0.0510
0.0000 (0.00%)
Apr 27 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.05 - 0.05
52 week 0.02 - 0.08
Open 0.05
Vol / Avg. 663,853.00/6.37M
Mkt cap 17.86M
P/E     -
Div/yield     -
EPS -0.01
Shares 408.81M
Beta     -
Inst. own     -
Feb 27, 2017
Interim 2017 Botanix Pharmaceuticals Ltd Earnings Release
  

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -11389.40% -
Operating margin -11201.55% -
EBITD margin - -
Return on average assets -81.33% -68.10%
Return on average equity -95.64% -77.48%
Employees 1 -
CDP Score - -

Address

Ground Floor, 16 Ord St
PERTH, WAS 6005
Australia
+61-8-94820580 (Phone)
+61-8-94820505 (Fax)

Website links

Description

Botanix Pharmaceuticals Limited, formerly Bone Medical Limited, is a pharmaceutical company. The Company focuses on developing medical dermatology products for dermatologists and their patients. Its segments include Research & Development and Corporate. The Company's products and pipeline products are all based on drug delivery technology known as Permetrex, which helps solve the challenge of delivering active pharmaceutical ingredients across the skin. The Company's products, which are under development, are focused on modulating the body's endocannabinoid system of receptors which regulates skin function, growth and renewal. Its product pipeline includes BTX1503, BTX1308 and BTX1204. Its BTX1503 is a transdermal gel formulation used for the treatment of serious acne in adults and teenagers. Its BTX1308 is a transdermal gel formulation used for the treatment of plaque psoriasis. Its BTX1204 is a transdermal gel formation used for the treatment of atopic dermititis.

Officers and directors

Graham Griffiths Chairman of the Board
William Bosch Executive Director
Matthew Callahan Executive Director
Simon L. Robertson Company Secretary
Robert E. T. Towner Director